Comparing Praxsyn (OTCMKTS:PXYN) & Century Therapeutics (NASDAQ:IPSC)

Praxsyn (OTCMKTS:PXYN) and Century Therapeutics (NASDAQ:IPSC) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership.

Valuation & Earnings

This table compares Praxsyn and Century Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxsyn	N/A	N/A	N/A	N/A	N/A
Century Therapeutics	$6.59 million	6.95	-$126.57 million	($0.29)	-1.83

Praxsyn has higher earnings, but lower revenue than Century Therapeutics.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Praxsyn and Century Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxsyn	0	0	0	0	0.00
Century Therapeutics	0	0	5	0	3.00

Century Therapeutics has a consensus target price of $4.20, suggesting a potential upside of 689.62%. Given Century Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Century Therapeutics is more favorable than Praxsyn.

Profitability

This table compares Praxsyn and Century Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Praxsyn	N/A	N/A	N/A
Century Therapeutics	-19.10%	-10.71%	-5.96%

Insider & Institutional Ownership

50.2% of Century Therapeutics shares are held by institutional investors. 5.0% of Century Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Century Therapeutics beats Praxsyn on 6 of the 9 factors compared between the two stocks.

About Praxsyn

Praxsyn Corporation, a health care company, provides medical practitioners with medications and services for their patients. It formulates non-narcotic and non-habit forming medications using therapeutic and preventative agents in the forms of transdermal creams, patches, and oral capsules for pain management, erectile dysfunction, and metabolic therapies. Praxsyn Corporation provides its products to patients covered under the California workers’ compensation system, as well as preferred provider contracts. The company was formerly known as The PAWS Pet Company, Inc. and changed its name to Praxsyn Corporation in March 2014. Praxsyn Corporation was founded in 2005 and is headquartered in Las Vegas, Nevada.

About Century Therapeutics

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.